sponsored
PatientsVille.com Logo

PatientsVille

Zyvox and Mononessa

Compare Side Effects

% of total side effects reported by users. DISCLAIMER: ALL DATA PROVIDED AS-IS. Data Source: openfda.gov.
Side EffectZyvoxMononessa
PREGNANCY ON ORAL CONTRACEPTIVE0% 4.3%
NAUSEA2.8% 4.1%
THROMBOCYTOPENIA4% 0%
DRUG INEFFECTIVE2.6% 3.9%
DRUG DOSE OMISSION0% 3.8%
DRUG INTERACTION3.3% 1.7%
ANAEMIA3.3% 0.4%
VOMITING2.5% 2.9%
HEADACHE0.8% 2.8%
SEROTONIN SYNDROME2.7% 0%
PLATELET COUNT DECREASED2.7% 0%
PAIN0.6% 2.6%
PRODUCT QUALITY ISSUE0% 2.5%
DIARRHOEA2.4% 1.5%
MATERNAL EXPOSURE DURING PREGNANCY0% 2.3%
PYREXIA2.2% 0.6%
METRORRHAGIA0% 2.2%
DEPRESSION0% 1.9%
SEPSIS1.9% 0%
DYSPNOEA1.8% 0.9%
PANCYTOPENIA1.8% 0%
DEATH1.8% 0%
PNEUMONIA1.7% 0%
LACTIC ACIDOSIS1.7% 0%
NEUROPATHY PERIPHERAL1.7% 0%
ANXIETY0.6% 1.6%
MENSTRUATION IRREGULAR0% 1.6%
OFF LABEL USE1.5% 1.4%
FATIGUE0.8% 1.5%
RESPIRATORY FAILURE1.5% 0%
VAGINAL HAEMORRHAGE0% 1.5%
PULMONARY EMBOLISM0% 1.5%
ABDOMINAL PAIN UPPER0% 1.4%
NO ADVERSE EVENT0% 1.4%
SEPTIC SHOCK1.3% 0%
DEEP VEIN THROMBOSIS0% 1.3%
RENAL FAILURE1.3% 0%
HYPOTENSION1.3% 0%
ASTHENIA1.3% 0%
RASH1.2% 1%
CONDITION AGGRAVATED1.2% 0.5%
STAPHYLOCOCCAL INFECTION1.2% 0%
HAEMOGLOBIN DECREASED1.2% 0%
MENORRHAGIA0% 1.1%
FEELING ABNORMAL0% 1.1%
INJURY0% 1.1%
CONFUSIONAL STATE1.1% 0%
ELECTROCARDIOGRAM QT PROLONGED1.1% 0%
BONE MARROW FAILURE1.1% 0%
DRUG RESISTANCE1.1% 0%
RENAL IMPAIRMENT1.1% 0%
MALAISE0.9% 1%
HYPERTENSION0.8% 1%
ABDOMINAL PAIN0.7% 1%
PARAESTHESIA0.6% 1%
ACUTE KIDNEY INJURY1% 0%
EXPOSURE DURING PREGNANCY0% 1%
THROMBOSIS0% 1%
PRODUCT DOSE OMISSION0% 1%
MIGRAINE0% 1%
DIZZINESS0.8% 0.9%
PAIN IN EXTREMITY0.5% 0.9%
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION0% 0.9%
MOOD SWINGS0% 0.9%
RENAL FAILURE ACUTE0.9% 0%
HYPONATRAEMIA0.8% 0%
DECREASED APPETITE0.8% 0%
NEUTROPENIA0.8% 0%
WEIGHT INCREASED0% 0.8%
SINUSITIS0% 0.8%
INJECTION SITE PAIN0% 0.8%
URTICARIA0% 0.8%
UNINTENDED PREGNANCY0% 0.8%
MUSCLE SPASMS0% 0.8%
DRUG EXPOSURE DURING PREGNANCY0% 0.8%
ACNE0% 0.8%
MULTI-ORGAN FAILURE0.8% 0%
WEIGHT DECREASED0.7% 0.6%
HYPERSENSITIVITY0.5% 0.7%
ABDOMINAL DISTENSION0% 0.7%
PALPITATIONS0% 0.7%
WHITE BLOOD CELL COUNT DECREASED0.7% 0%
BLOOD CREATININE INCREASED0.7% 0%
INFECTION0.7% 0%
TOXICITY TO VARIOUS AGENTS0.7% 0%
PATHOGEN RESISTANCE0.7% 0%
TREMOR0.7% 0%
GENERAL PHYSICAL HEALTH DETERIORATION0.7% 0%
TACHYCARDIA0.7% 0%
PRODUCT USE IN UNAPPROVED INDICATION0.6% 0.6%
CONVULSION0.6% 0.6%
PRURITUS0.5% 0.6%
HYPOAESTHESIA0.5% 0.6%
OEDEMA PERIPHERAL0.5% 0.6%
CHEST PAIN0.4% 0.6%
INSOMNIA0.4% 0.6%
BACK PAIN0% 0.6%
METABOLIC ACIDOSIS0.6% 0%
CARDIAC FAILURE0.6% 0%
URINARY TRACT INFECTION0.6% 0%
SLEEP DISORDER0% 0.6%
HYPOGLYCAEMIA0.6% 0%
HYPOKALAEMIA0.6% 0%
ENTEROCOCCAL INFECTION0.6% 0%
ASPARTATE AMINOTRANSFERASE INCREASED0.6% 0%
ALANINE AMINOTRANSFERASE INCREASED0.6% 0%
LEUKOPENIA0.6% 0%
DRUG HYPERSENSITIVITY0.6% 0%
ALOPECIA0% 0.6%
GALLBLADDER DISORDER0% 0.6%
PSORIASIS0% 0.6%
PHARMACEUTICAL PRODUCT COMPLAINT0% 0.6%
OVARIAN CYST0% 0.6%
MEMORY IMPAIRMENT0% 0.6%
CHOLELITHIASIS0% 0.6%
INJECTION SITE ERYTHEMA0% 0.6%
PRODUCT SUBSTITUTION ISSUE0% 0.6%
INJECTION SITE REACTION0% 0.6%
ASTHMA0% 0.6%
FLUSHING0% 0.6%
ERYTHEMA0.5% 0.4%
ARTHRALGIA0.4% 0.5%
CHEST DISCOMFORT0% 0.5%
SOMNOLENCE0% 0.5%
CHOLECYSTITIS CHRONIC0% 0.5%
THERAPEUTIC RESPONSE UNEXPECTED WITH DRUG SUBSTITUTION0% 0.5%
EMOTIONAL DISORDER0% 0.5%
EMOTIONAL DISTRESS0% 0.5%
HEART RATE INCREASED0% 0.5%
NASOPHARYNGITIS0% 0.5%
POLYMENORRHOEA0% 0.5%
OPTIC NEUROPATHY0.5% 0%
DISSEMINATED INTRAVASCULAR COAGULATION0.5% 0%
HEPATIC FAILURE0.5% 0%
GASTROINTESTINAL HAEMORRHAGE0.5% 0%
VISION BLURRED0.5% 0%
COUGH0.5% 0%
TREATMENT FAILURE0.5% 0%
PLEURAL EFFUSION0.5% 0%
CARDIAC ARREST0.5% 0%
DYSGEUSIA0.5% 0%
FEBRILE NEUTROPENIA0.5% 0%
INTERNATIONAL NORMALISED RATIO INCREASED0.5% 0%
HALLUCINATION0.5% 0%
AGITATION0.5% 0%
WHITE BLOOD CELL COUNT INCREASED0.5% 0%
CELLULITIS0.5% 0%
INCORRECT DOSE ADMINISTERED0% 0.4%
IRRITABILITY0% 0.4%
PANIC ATTACK0% 0.4%
INJECTION SITE SWELLING0% 0.4%
SWELLING0% 0.4%
SWELLING FACE0% 0.4%
UNEVALUABLE EVENT0% 0.4%
INJECTION SITE PRURITUS0% 0.4%
MENTAL STATUS CHANGES0.4% 0%
HOT FLUSH0% 0.4%
CEREBROVASCULAR ACCIDENT0% 0.4%
PRODUCT USE ISSUE0.4% 0%
VISUAL IMPAIRMENT0.4% 0%
DEHYDRATION0.4% 0%
TOXIC EPIDERMAL NECROLYSIS0.4% 0%
BLOOD BILIRUBIN INCREASED0.4% 0%
INTENTIONAL PRODUCT USE ISSUE0.4% 0%
ABNORMAL DREAMS0% 0.3%
ACCIDENTAL EXPOSURE TO PRODUCT BY CHILD0% 0.3%
ADVERSE DRUG REACTION0% 0.3%
AMENORRHOEA0% 0.3%

New treatments are found every day. View current Zyvox research studies and Mononessa clinical trials

1